Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report

Philip S. Schein; Philip T. Lavin; Charles G. Moertel; Stephen Frytak; Richard G. Hahn; Michael J. O'Connell; Richard J. Reitemeier; Joseph Rubin; Allen J. Schutt; Louis H. Weiland; M. Kalser; J. Barkin; H. Lessner; R. Mann‐Kaplan; D. Redlhammer; M. Silverman; M. Troner; H. O. Douglass; S. Milliron; J. Lokich; J. Brooks; J. Chaffe; A. Like; N. Zamcheck; K. Ramming; J. Bateman; H. Spiro; E. Livstone; A. Knowlton

doi:10.1002/1097-0142(197807)42:1<19::AID-CNCR2820420103>3.0.CO;2-4

Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report

Philip S. Schein, Philip T. Lavin, Charles G. Moertel, Stephen Frytak, Richard G. Hahn, Michael J. O'Connell, Richard J. Reitemeier, Joseph Rubin, Allen J. Schutt, Louis H. Weiland, M. Kalser, J. Barkin, H. Lessner, R. Mann‐Kaplan, D. Redlhammer, M. Silverman, M. Troner, H. O. Douglass, S. Milliron, J. LokichJ. Brooks, J. Chaffe, A. Like, N. Zamcheck, K. Ramming, J. Bateman, H. Spiro, E. Livstone, A. Knowlton

Medicine

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

Sixty-six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin-D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used for objective assessment of response. For adriamycin, 2 of 25 patients (8%) evidenced a partial response (2 of 15 (13%) previously untreated patients). One of 25 patients treated with methotrexate and one of 28 who received actinomycin-D responded. The duration of responses ranged from 43-64 days for those patients with no chemotherapy prior to study entry. The median survival of patients who received adriamycin as initial treatment was 12 weeks compared to 8 weeks for methotrexate and 6 weeks for actinomycin-D therapy.

Original language	English (US)
Pages (from-to)	19-22
Number of pages	4
Journal	Cancer
Volume	42
Issue number	1
DOIs	https://doi.org/10.1002/1097-0142(197807)42:1<19::AID-CNCR2820420103>3.0.CO;2-4
State	Published - Jul 1978

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(197807)42:1<19::AID-CNCR2820420103>3.0.CO;2-4

Fingerprint Dive into the research topics of 'Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report'. Together they form a unique fingerprint.

Cite this

Schein, P. S., Lavin, P. T., Moertel, C. G., Frytak, S., Hahn, R. G., O'Connell, M. J., Reitemeier, R. J., Rubin, J., Schutt, A. J., Weiland, L. H., Kalser, M., Barkin, J., Lessner, H., Mann‐Kaplan, R., Redlhammer, D., Silverman, M., Troner, M., Douglass, H. O., Milliron, S., ... Knowlton, A. (1978). Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report. Cancer, 42(1), 19-22. https://doi.org/10.1002/1097-0142(197807)42:1<19::AID-CNCR2820420103>3.0.CO;2-4

Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report. / Schein, Philip S.; Lavin, Philip T.; Moertel, Charles G.; Frytak, Stephen; Hahn, Richard G.; O'Connell, Michael J.; Reitemeier, Richard J.; Rubin, Joseph; Schutt, Allen J.; Weiland, Louis H.; Kalser, M.; Barkin, J.; Lessner, H.; Mann‐Kaplan, R.; Redlhammer, D.; Silverman, M.; Troner, M.; Douglass, H. O.; Milliron, S.; Lokich, J.; Brooks, J.; Chaffe, J.; Like, A.; Zamcheck, N.; Ramming, K.; Bateman, J.; Spiro, H.; Livstone, E.; Knowlton, A.

In: Cancer, Vol. 42, No. 1, 07.1978, p. 19-22.

Research output: Contribution to journal › Article › peer-review

Schein, PS, Lavin, PT, Moertel, CG, Frytak, S, Hahn, RG, O'Connell, MJ, Reitemeier, RJ, Rubin, J, Schutt, AJ, Weiland, LH, Kalser, M, Barkin, J, Lessner, H, Mann‐Kaplan, R, Redlhammer, D, Silverman, M, Troner, M, Douglass, HO, Milliron, S, Lokich, J, Brooks, J, Chaffe, J, Like, A, Zamcheck, N, Ramming, K, Bateman, J, Spiro, H, Livstone, E & Knowlton, A 1978, 'Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report', Cancer, vol. 42, no. 1, pp. 19-22. https://doi.org/10.1002/1097-0142(197807)42:1<19::AID-CNCR2820420103>3.0.CO;2-4

Schein, Philip S. ; Lavin, Philip T. ; Moertel, Charles G. ; Frytak, Stephen ; Hahn, Richard G. ; O'Connell, Michael J. ; Reitemeier, Richard J. ; Rubin, Joseph ; Schutt, Allen J. ; Weiland, Louis H. ; Kalser, M. ; Barkin, J. ; Lessner, H. ; Mann‐Kaplan, R. ; Redlhammer, D. ; Silverman, M. ; Troner, M. ; Douglass, H. O. ; Milliron, S. ; Lokich, J. ; Brooks, J. ; Chaffe, J. ; Like, A. ; Zamcheck, N. ; Ramming, K. ; Bateman, J. ; Spiro, H. ; Livstone, E. ; Knowlton, A. / Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report. In: Cancer. 1978 ; Vol. 42, No. 1. pp. 19-22.

@article{68e2d95e445f442e96a0c254c6a3b1a2,

title = "Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report",

abstract = "Sixty-six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin-D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used for objective assessment of response. For adriamycin, 2 of 25 patients (8%) evidenced a partial response (2 of 15 (13%) previously untreated patients). One of 25 patients treated with methotrexate and one of 28 who received actinomycin-D responded. The duration of responses ranged from 43-64 days for those patients with no chemotherapy prior to study entry. The median survival of patients who received adriamycin as initial treatment was 12 weeks compared to 8 weeks for methotrexate and 6 weeks for actinomycin-D therapy.",

author = "Schein, {Philip S.} and Lavin, {Philip T.} and Moertel, {Charles G.} and Stephen Frytak and Hahn, {Richard G.} and O'Connell, {Michael J.} and Reitemeier, {Richard J.} and Joseph Rubin and Schutt, {Allen J.} and Weiland, {Louis H.} and M. Kalser and J. Barkin and H. Lessner and R. Mann‐Kaplan and D. Redlhammer and M. Silverman and M. Troner and Douglass, {H. O.} and S. Milliron and J. Lokich and J. Brooks and J. Chaffe and A. Like and N. Zamcheck and K. Ramming and J. Bateman and H. Spiro and E. Livstone and A. Knowlton",

year = "1978",

month = jul,

doi = "10.1002/1097-0142(197807)42:1<19::AID-CNCR2820420103>3.0.CO;2-4",

language = "English (US)",

volume = "42",

pages = "19--22",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report

AU - Schein, Philip S.

AU - Lavin, Philip T.

AU - Moertel, Charles G.

AU - Frytak, Stephen

AU - Hahn, Richard G.

AU - O'Connell, Michael J.

AU - Reitemeier, Richard J.

AU - Rubin, Joseph

AU - Schutt, Allen J.

AU - Weiland, Louis H.

AU - Kalser, M.

AU - Barkin, J.

AU - Lessner, H.

AU - Mann‐Kaplan, R.

AU - Redlhammer, D.

AU - Silverman, M.

AU - Troner, M.

AU - Douglass, H. O.

AU - Milliron, S.

AU - Lokich, J.

AU - Brooks, J.

AU - Chaffe, J.

AU - Like, A.

AU - Zamcheck, N.

AU - Ramming, K.

AU - Bateman, J.

AU - Spiro, H.

AU - Livstone, E.

AU - Knowlton, A.

PY - 1978/7

Y1 - 1978/7

N2 - Sixty-six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin-D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used for objective assessment of response. For adriamycin, 2 of 25 patients (8%) evidenced a partial response (2 of 15 (13%) previously untreated patients). One of 25 patients treated with methotrexate and one of 28 who received actinomycin-D responded. The duration of responses ranged from 43-64 days for those patients with no chemotherapy prior to study entry. The median survival of patients who received adriamycin as initial treatment was 12 weeks compared to 8 weeks for methotrexate and 6 weeks for actinomycin-D therapy.

AB - Sixty-six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin-D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used for objective assessment of response. For adriamycin, 2 of 25 patients (8%) evidenced a partial response (2 of 15 (13%) previously untreated patients). One of 25 patients treated with methotrexate and one of 28 who received actinomycin-D responded. The duration of responses ranged from 43-64 days for those patients with no chemotherapy prior to study entry. The median survival of patients who received adriamycin as initial treatment was 12 weeks compared to 8 weeks for methotrexate and 6 weeks for actinomycin-D therapy.

UR - http://www.scopus.com/inward/record.url?scp=0018182894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018182894&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197807)42:1<19::AID-CNCR2820420103>3.0.CO;2-4

DO - 10.1002/1097-0142(197807)42:1<19::AID-CNCR2820420103>3.0.CO;2-4

M3 - Article

C2 - 352505

AN - SCOPUS:0018182894

VL - 42

SP - 19

EP - 22

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -